A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event

Virology

Volumn 233, Issue 2, 1997, Pages 313-326

  McInerney, Tracey L ^a   McLain, Lesley ^a   Armstrong, Sylvia J ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ARTICLE; BINDING SITE; CELL FUSION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA A VIRUS; POLIOVIRUS;

EID: 0030850077     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8547     Document Type: Article

References (55)

1. Armstrong, S. J., and Dimmock, N. J. (1992). Neutralization of influenza virus by low concentrations of HA-specific polymeric IgA inhibits viral fusion activity but activation of the ribonucleoprotein is also inhibited. J. Virol. 66, 3823-3832.
2. Armstrong, S. J., and Dimmock, N. J. (1996). Varying temperature-dependence of post-attachment neutralization of human immunodeficency virus type 1 by monoclonal antibodies to gp120: Identification of a very early fusion-independent event as a neutralization target. J. Gen. Virol. 77, 1397-1402.
3. Armstrong, S. J., McInerney, T. L., McLain, L., Wahren, B., Hinkula, J., Levi, M., and Dimmock, N. J. (1996). Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77, 2931-2941.
4. Barbas III, C. F., Björling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T. M., Zebedee, S. L., Persson, M. A. A., Nara, P. L., Norrby, E., and Burton, D. R. (1992). Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89, 9339-9343.
5. Barbas III, C. F., Collet, T. A., Amberg, W., Roben, P., Binley, J. M., Hoekstra, D., Cababa, D., Jones, T. M., Williamson, R. A., Pilkington, G. R., Haigwood, N. L., Cabezas, E., Satterthwait, A. C., Sanz, I., and Burton, D. R. (1993). Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230, 812-823.
6. Barbas III, C. F., Hu, D., Dunlop, N., Sawyer, L., Cababa, D., Hendry, R. M., Nara, P. L., and Burton, D. R. (1994). In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91, 3809-3813.
7. Bracci, L. C., Antoni, G., Cusi, M. G., Lozzi, L., Niccoli, N., Pereni, S., Rustici, M., Santucci, A., Soldani, P., Valensin, P. E., and Neri, P. (1988). Antipeptide monoclonal antibodies inhibit the binding of rabies virus glycoprotein and alpha-bungarotoxin to the nicotinic acetylcholine receptor. Mol. Immunol. 25, 881-888.
8. Bukrinskaya, A. G., Ghorpade, A., Heinzinger, N. K., Smithgall, T. E., Lewis, R. E., and Stevenson, M. (1996). Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc. Natl. Acad. Sci. USA 93, 367-371.
9. Burton, D. R., Barbas III, C. F., Persson, M. A. A., Koenig, S., Chanock, R. M., and Lerner, R. A. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137.
10. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, E., Stiehm, E. R., Bryson, Y. J., Cao, Y., Moore, J. P., Ho, D. D., and Barbas III, C. F. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
11. Cusi, M. G., Valensin, P. E., Tollis, M., Bracci, L., Petreni, S., and Soldani, P. (1991). Binding properties of monoclonal antibodies to rabies virus. Microbiol. 14, 205-211.
12. Dimmock, N. J. (1993). Neutralization of animal viruses. Curr. Topics Microbiol. Immunol. 183, 1-149.
13. Dimmock, N. J. (1995). Update on the neutralization of animal viruses. Rev. Med. Virol. 5, 165-179.
14. Gallay, P., Swingler, S., Aiken, C., and Trono, D. (1995). HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80, 379-388.
15. Gelderblom, H. R., Hausmann, E. H. S., Özel, M., Pauli, G., and Koch, M. A. (1987). Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 156, 171-176.
16. Gopalakrishnan, P. V., and Karush, F. (1974). Antibody affinity. VI. Synthesis of bivalent lactosyl haptens and their interaction with antilactosyl antibodies. Immunochemistry 11, 279-283.
17. + cells from virus binding. J. Exp. Med. 172, 1233-1242.
18. Hill, C. P., Worthylake, D., Bancroft, D. P., Christensen, A. M., and Sundquist, W. I. (1996). Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Proc. Natl. Acad. Sci. USA 93, 3099-3104.
19. Ho, D. D., Kaplan, J. C., Rackauskas, I. E., and Gurney, M. E. (1988). Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239, 1021-1023.
20. Hoekstra, D., de Boer, T., Klappe, K., and Wilschut, J. (1984). Fluorescence method for measuring kinetics of fusion between biological membranes. Biochemistry 23, 5675-5681.
21. Icenogle, J., Shiwen, H., Duke, G., Gilbert, S., Rueckert, R., and Anderegg, J. (1983). Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry. Virology 127, 412-425.
22. Iorio, R. M., Glickman, R. L., Riel, A. M., Sheehan, J. P., and Bratt, M. A. (1989). Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: Monoclonal antibodies to some sites prevent attachment. Virus Res. 13, 245-262.
23. Krust, B., Callebaut, C., and Hovanessian, A. G. (1993). Inhibition of entry of HIV into cells by poly(A)-poly(U). AIDS Res. Human Retroviruses 9, 1087-1090.
24. Lasky, L. A., Nakamura, G., Smith, D. H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T., and Capon, D. J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975-985.
25. Loyter, A., Citovsky, V., and Blumenthal, R. (1988). The use of fluorescence dequenching measurements to follow viral membrane fusion events. Methods Biochem. Anal. 33, 129-164.
26. Maddon, P. J., Dalgleish, A. G., McDougal, J. S., Clapham, P. R., Weiss, R. A., and Axel, R. (1986). The T4 receptor encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348.
27. Mandel, B. (1985). Virus neutralization. In "Immunochemistry of Viruses. The Basis for Serodiagnosis and Vaccines" (M. H. V. van Regenmortel and A. R. Neurath, Eds.), pp. 53-70. Elsevier Science Publishers B.V., Amsterdam.
28. Marsh, M., and Pelchen-Matthews, A. (1993). Entry of animal viruses into cells. Rev. Med. Virol. 3, 173-185.
29. McDougal, J. S., Nicholson, J. K. A., Cross, G. D., Cort, S. P., Kennedy, M. S., and Mawle, A. C. (1986). Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: Conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J. Immunol. 137, 2937-2944.
30. McKeating, J. A., McKnight, A., and Moore, J. P. (1991). Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization. J. Virol. 65, 852-860.
31. McLain, L., and Dimmock, N. J. (1994). Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75, 1457-1460.
32. McLain, L., and Dimmock, N. J. (1997). A human CD4+ T cell line expresses functional CD64 (FcγRI), CD32 (FcγRII), and CD16 (FcγRIII) receptors, but these do not enhance the infectivity of HIV-1-IgG complexes. Immunology 90, 109-114.
33. Montefiori, D. C., Graham, B. S., Zhou, J., Bucco, R. A., Schwartz, D. H., Cavacini, L. A., Posner, M. R., and NIH-NIAID AIDS Vaccine Clinical Trials Network (1993). V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Invest. 92, 840-847.
34. Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: The consequences of viral adaption to growth on transformed T cells. AIDS 9(Suppl. A), S117-S136.
35. Moore, J. P., McKeating, J. A., Weiss, R. A., and Sattentau, Q. J. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250, 1139-1142.
36. Mosser, A. G., Leippe, D., and Rueckert, R. R. (1989). Neutralization of picornaviruses: Support for the pentamer bridging hypothesis. In "Molecular Aspects of Picornavirus Infection and Detection" (B. L. Semler, and E. Ehrenfeld, Eds.), pp. 155-167. Am. Soc. Microbiol., Washington.
37. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., and Katinger, H. R. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647.
38. Nermut, M. V., Hashmi, G. S., and Hockley, D. J. (1993). Further evidence of icosahedral symmetry in human and simian immunodeficiency virus. AIDS Res. Human Retroviruses 9, 929-938.
39. Pinter, A., Honnen, W. J., Tilley, S. A., Bona, C., Zaghouani, H., Gorny, M. K., and Zolla-Pazner, S. (1989). Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63, 2674-2679.
40. Pinter, A., Honnen, W. J., and Tilley, S. A. (1993b). Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J. Virol. 67, 5692-5697.
41. Poignard, P., Klasse, P. J., and Sattentau, Q. J. (1996). Antibody neutralization of HIV-1. Immunol. Today 17, 239-246.
42. Posner, M. R., Hideshima, T., Cannon, T., Mukherjee, M., Mayer, K. H., and Byrn, R. A. (1991). An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146, 4325-4332.
43. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas III, C. F., and Burton, D. R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828.
44. Sattentau, Q. J. (1996). Neutralization of HIV-1 by antibody. Curr. Opin. Immunol. 8, 540-545.
45. Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182, 185-196.
46. Sawyer, L. S. W., Wrin, M. T., Crawford-Miksza, L., Potts, B., Wu, Y., Weber, P. A., Alfonso, R. D., and Hanson, C. V. (1994). Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68, 1342-1349.
47. Schawaller, M., Smith, G. E., Skehel, J. J., and Wiley, D. C. (1989). Studies with crosslinking reagents on the oligomeric structure of the env-glycoprotein of HIV. Virology 172, 367-369.
48. Schnittman, S. M., Lane, H. C., Roth, J., Burrows, A., Folks, T. M., Kehrl, J. H., Koenig, S., Berman, P., and Fauci, A. S. (1988). Characterization of gp120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J. Immunol. 141, 4181-4186.
49. Skinner, M. A., Langlois, A. J., McDanal, C. B., McDougal, J. S., Bolognesi, D. P., and Matthews, T. J. (1988). Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 62, 4195-4200.
50. Sinangil, F., Loyter, A., and Volsky, D. (1988). Quantitative measurements of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching. FEBS Lett. 239, 88-92.
51. Smith, T. J., Olson, N. H., Cheng, R. H., Liu, H., Chase, E. S., Lee, W. M., Leippe, D. M., Mosser, A. G., Rueckert, R. R., and Baker, T. S. (1993). Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J. Virol. 67, 1148-1158.
52. Sun, N.-C., Ho, D. D., Sun, C. R. Y., Liou, R.-S., Gordon, W., Fung, M. S. C., Li, X.-L., Ting, R. C., Lee, T.-H., Chang, N. T., and Chang, T.-W. (1989). Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J. Virol. 63, 3579-3585.
53. Thomas, A. A. M., Brioen, P., and Boeyé, A. (1985). A monoclonal antibody that neutralizes poliovirus by cross-linking virions. J. Virol. 54, 7-13.
54. Valentine, R. C., and Green, N. M. (1967). Electron microscopy of an antibody-hapten complex. J. Mol. Biol. 27, 615-617.
55. Werner, T. C., Bunting, J. R., and Cathon, R. E. (1972). The shape of immunoglobulin G molecules in solution. Proc. Natl. Acad. Sci. USA 69, 795-799.